Alessandra Vergori

Prof. Dr. Alessandra Vergori

HIV/AIDS Department, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2022 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
AAAndrea Antinori
Andrea Antinori
SCStefania Cicalini
Stefania Cicalini
SMSilvia Meschi
Silvia Meschi
VBVeronica Bordoni
Veronica Bordoni
PLPatrizia Lorenzini
Patrizia Lorenzini
FVFrancesco Vaia
Francesco Vaia
Data on SARS-CoV-2 vaccine immunogenicity in PLWH are currently limited. Aim of the study was to investigate immunogenicity according to current CD4 T-cell count PLWH on ART attending a SARS-CoV-2 vaccination program, were included in a prospective immunogenicity evaluation after receiving BNT162b2 or mRNA-1273. Participants were stratified by current CD4 T-cell count (poor CD4 recovery, PCDR: 500/mm3). RBD-binding IgG, SARS-CoV-2 neutralizing antibodies (nAbs) and IFN-γ release were measured. As control group, HIV-negative healthcare workers (HCWs) were used Among 166 PLWH, after 1 month from the booster dose, detectable RBD-binding IgG were elicited in 86.7% of PCDR, 100% of ICDR, 98.7% of HCDR, and a neutralizing titre ≥1:10 elicited in 70.0%, 88.2%, and 93.1%, respectively. Compared to HCDR, all immune response parameters were significantly lower in PCDR. After adjusting for confounders, current CD4 T-cell <200/mm3 significantly predicted a poor magnitude of anti-RDB, nAbs and IFN-γ response. As compared with HCWs, PCDR elicited a consistently reduced immunogenicity for all parameters, ICDR only a reduced RBD-binding antibody response, whereas HCDR elicited a comparable immune response for all parameters Humoral and cell-mediated immune response against SARS-CoV-2 were elicited in most of PLWH, albeit significantly poorer in those with CD4 T-cell 500 cell/mm3 and HIV-negative controls. A lower RBD-binding antibody response than HCWs was also observed in PLWH with CD4 T-cell 200–500/mm3, whereas immune response elicited in PLWH with a CD4 T-cell >500/mm3 was comparable to HIV-negative population

22 August 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
AVAlessandra Vergori
Alessandra Vergori
ALAlessandro Cozzi Lepri
Alessandro Cozzi Lepri
SCStefania Cicalini
Stefania Cicalini
GMGiulia Matusali
Giulia Matusali
VBVeronica Bordoni
Veronica Bordoni
AAAndrea Antinori
Andrea Antinori
In order to investigate safety and immunogenicity of SARS-CoV-2 vaccine third dose in people living with HIV (PLWH), we analyze anti-RBD, microneutralization assay and IFN-γ production in 216 PLWH on ART with advanced disease (CD4 count <200 cell/mm3 and/or previous AIDS) receiving the third dose of a mRNA vaccine (BNT162b2 or mRNA-1273) after a median of 142 days from the second dose. Median age is 54 years, median CD4 nadir 45 cell/mm3 (20–122), 93% HIV-RNA < 50 c/mL. In 68% of PLWH at least one side-effect, generally mild, is recorded. Humoral response after the third dose was strong and higher than that achieved with the second dose (>2 log2 difference), especially when a heterologous combination with mRNA-1273 as third shot is used. In contrast, cell-mediated immunity remain stable. Our data support usefulness of third dose in PLWH currently receiving suppressive ART who presented with severe immune dysregulation.

25 September 2020 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
AMAnnalisa Mondi
Annalisa Mondi
ECEleonora Cimini
Eleonora Cimini
FCFrancesca Colavita
Francesca Colavita
SCStefania Cicalini
Stefania Cicalini
CPCarmela Pinnetti
Carmela Pinnetti
AAAndrea Antinori
Andrea Antinori

Verified
Journal Article
Open access
PDF file
CAChiara Agrati
Chiara Agrati
ASAlessandra Sacchi
Alessandra Sacchi
ETEleonora Tartaglia
Eleonora Tartaglia
AVAlessandra Vergori
Alessandra Vergori
RGRoberta Gagliardini
Roberta Gagliardini
MBMichele Bibas
Michele Bibas
In severe COVID-19, which is characterized by blood clots and neutrophil-platelet aggregates in the circulating blood and different tissues, an increased incidence of cardiovascular complications and venous thrombotic events has been reported. The inflammatory storm that characterizes severe infections may act as a driver capable of profoundly disrupting the complex interplay between platelets, endothelium, and leukocytes, thus contributing to the definition of COVID-19-associated coagulopathy. In this frame, P-selectin represents a key molecule expressed on endothelial cells and on activated platelets, and contributes to endothelial activation, leucocyte recruitment, rolling, and tissue migration. Briefly, we describe the current state of knowledge about P-selectin involvement in COVID-19 pathogenesis, its possible use as a severity marker and as a target for host-directed therapeutic intervention.

1 April 2019 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
GSGAETANA STERRANTINO
GAETANA STERRANTINO
VBVanni Borghi
Vanni Borghi
ACAnna Paola Callegaro
Anna Paola Callegaro
BBBianca Bruzzone
Bianca Bruzzone
Francesco SaladiniFrancesco Saladini
Francesco Saladini
MZMauro Zaccarelli
Mauro Zaccarelli

25 January 2021 in Annals of Medicine
Verified
Journal Article
Open access
AVAlessandra Vergori
Alessandra Vergori
EPElisa Pianura
Elisa Pianura
PLPatrizia Lorenzini
Patrizia Lorenzini
ADAlessandra D’aBramo
Alessandra D’aBramo
FSFederica Di Stefano
Federica Di Stefano
OGon behalf of the ReCOVeRI Study Group
on behalf of the ReCOVeRI Study Group
Critically ill patients with COVID-19 are at increased risk of developing a hypercoagulable state due to haemostatic changes directly related to the SARS-CoV-2 infection or to the consequence of th...